INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID−) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.
6 May 2011 in International Urology and Nephrology
Background and Objectives: This study aimed to evaluate the relationship between mortality and cardiac laboratory findings in patients who were hospitalized after a positive PCR for COVID-19 infection. Materials and Methods: This study included patients who were admitted to or referred to the hospital between 20 March and 20 June 2020, diagnosed with COVID-19 via a positive RT-PCR from nasal and pharyngeal swab samples. The troponin I level was measured from each patient. Medical records of patients were retrospectively reviewed and analyzed. Results: A hundred and five patients who were diagnosed with COVID-19 and hospitalized, or who died in the hospital due to COVID-19, were included in this study. There was a statistically significant difference between the troponin I high and low level groups in terms of age (years), BMI, shortness of breath (SB), oxygen saturation (%), hypertension, length of stay in the ICU; and for mortality, C-reactive protein, the neutrophil-to-lymphocyte ratio, hemoglobin, lactate dehydrogenase, ferritin, D-dimer, creatine kinase-MB, prothrombin time, calcium, and 25-hydroxy vitamin 25(OH)D3 (all p < 0.05). In the logistic analyses, a significant association was noted between troponin I and the adjusted risk of mortality. A ROC curve analysis identified troponin I values > 7.8 pg/mL as an effective cut-off point in mortality for patients with COVID-19. A troponin I value of higher than 7.8 pg/mL yielded a sensitivity of 78% and a specificity of 86%. Conclusions: The hospital mortality rate was higher among patients diagnosed with COVID-19 accompanied by troponin levels higher than 7.8 pg/mL. Therefore, in patients diagnosed with COVID-19, elevated troponin I levels >7.8 pg/mL can be considered an independent risk factor for mortality.
Background: Distinguishing expected postoperative inflammation from early infection remains challenging after thoracic surgery; serial C-reactive protein (CRP) is widely used to aid this differentiation. Methods: We conducted a single-centre retrospective cohort study of adults undergoing thoracic surgery (1 January 2022–31 December 2024). CRP was measured preoperatively and on postoperative days (POD) 1–5; trajectories were compared by surgical approach and extent of resection using repeated-measures ANOVA with Greenhouse–Geisser correction (α = 0.05). Results: Among 144 patients (VATS n = 79; open thoracotomy n = 65; extent: segmentectomy n = 25, lobectomy n = 96, bilobectomy n = 9, pneumonectomy n = 14), overall CRP rose from 26.6 ± 45.0 mg/L preoperatively to a POD2 peak of 200.9 ± 72.7 mg/L, then declined to 118.1 ± 70.7 mg/L by POD5. Thoracotomy showed higher peaks than VATS (POD2 216.1 ± 76.0 vs. 152.3 ± 29.9 mg/L; POD3 206.7 ± 88.7 vs. 159.8 ± 72.4 mg/L), but time × approach was not statistically significant (F = 1.042, p = 0.381; partial η2 = 0.115). The extent analysis showed the highest peaks with pneumonectomy (POD2 273.7 ± 46.3 mg/L) compared with bilobectomy (155.7 ± 11.0 mg/L) and lobectomy (VATS 132.1 ± 3.7, open 196.8 ± 85.3 mg/L); time × extent was not significant (F = 1.136, p = 0.384; partial η2 = 0.299). The overall effect of time did not reach significance (F = 1.127, p = 0.352; partial η2 = 0.124), reflecting variability. Patients with clinically diagnosed infections exhibited more prolonged CRP elevation, often >100 mg/L beyond POD4, whereas uncomplicated cases declined after the POD2 peak; these trends did not achieve statistical significance in this cohort. Conclusions: Early postoperative CRP in thoracic surgery typically peaks at 48–72 h and then falls. Higher peaks with open surgery and more extensive resection were observed but not statistically confirmed; persistence > 100 mg/L after POD3–4 may flag complications. Prospective studies are needed to validate thresholds and refine CRP-based surveillance pathways.
9 April 2025 in Occupational Therapy In Health Care
The Sars-Cov-2 infection disease (COVID-19) causes symptoms during both acute and post-COVID phases. This study assessed exercise capacity and occupational competence of 20 hospitalized COVID-19 patients, at discharge and three months later using the 6-Minute Step Test and Occupational Self-Assessment. Significant differences were found in both exercise capacity and occupational competence scores between discharge and three months later (p < 0.05). However, these measurements were not correlated (p > 0.05). Although patients show improvement after discharge, some symptoms persisted, affecting their exercise, and occupational performance. Further research is needed to explore long-term occupational outcomes of COVID-19 beyond one year.